Zephyr AI: Pioneering the Future of Precision Medicine
In the dynamic world of healthcare, a McLean-based startup, Zephyr AI, is making waves with its groundbreaking approach to precision medicine and a newly successful funding round. Established in 2020, Zephyr AI is on a mission to democratize personalized treatment by harnessing the power of artificial intelligence (AI) to extract meaningful insights from complex healthcare data.
Zephyr AI’s innovative algorithms aim to address a pressing need in the medical field: the ability to deliver precise, individualized treatments without waiting for the next generation of high-fidelity data. As Jeff Sherman, co-founder and interim CEO, emphasizes, the company operates with a sense of urgency to provide solutions for patients today.
Precision medicine, the focus of Zephyr AI, tailors medical management decisions to the unique genomic, environmental, and lifestyle factors of each patient. This approach promises to transform the treatment landscape for diseases such as cancer and heart disease by offering targeted and effective therapies.
In a significant milestone, Zephyr AI secured $111 million in a Series A funding round in March, attracting investments from prominent entities like Revolution Growth and Eli Lilly & Co. This funding is set to accelerate the development of their AI-driven algorithms and expand their capacity to analyze vast datasets for more nuanced medical insights.
The company was co-founded by industry visionaries Grant Verstandig and Yisroel Brumer, who bring a wealth of experience from healthcare and defense sectors. Under their leadership, Zephyr AI is gearing up to significantly expand its team, particularly in science, engineering, and business development.
A key factor in Zephyr AI’s success has been its ability to demonstrate the real-world effectiveness of its algorithms. During investor demos, the company showcased how their technology can distinguish between patients with similar clinical profiles who respond differently to treatments. This capability underscores the potential of AI to revolutionize personalized medicine by ensuring that patients receive the most effective therapies based on their unique characteristics.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
